Results 131 to 140 of about 13,721,448 (320)

Simultaneous detection of FV Q506 and prothrombin 20210 A variation by allele-specific PCR

Haematologica, 1999
BACKGROUND AND OBJECTIVE: Factor V Leiden is the most important risk factor for hereditary thromboembolism, whereas the mutation in the 3'-untranslated region of the prothrombin gene seems to be only a mild risk factor for thrombotic events. On the other
M Mitterer, AJ Lanthaler, W Mair, K Giacomuzzi, P Coser   +4 more
doaj  

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Factor V leiden thrombophilia

Clinical characteristics: Factor V Leiden thrombophilia is characterized by venous thromboembolism (VTE) manifesting most commonly in adults as deep vein thrombosis (DVT) in the legs or pulmonary embolism.
Pastori, Daniele, Pignatelli Pasquale, Menichelli, Danilo, Valeriani, Emanuele   +3 more
core  

Characterizing the Epithelial Transcriptome of Type‐2 High Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
Brian Cameron, Jeffanie Gayoso, Christina Dorismond, Ping Li, Mason Krysinski, Rakesh Chandra, Justin Turner, Naweed Chowdhury   +7 more
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Historisch Leiden in Kaart: 1585 Register Vetus / 1588 Straten- en Grachtenboek / 1601 Oud Belastingboek / 1606: Schoorsteengeld /1642 Bonboek

, 2016
Deze kaart vormt een geografische koppeling van een aantal bronnen van Erfgoed Leiden en Omstreken, te weten: 1588 Straten- en Grachtenboek 1585 Vetus 1601 Oud-Belastingboek 1606 Schoorsteengeld 1642 Bonboek Wanthuis (Zie 'Relations' voor links naar de
Gehring, E. (Erfgoed Leiden en Omstreken)
core   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

Factor v Leiden homozygous genotype and pregnancy outcomes.

, 2009
International audienceOBJECTIVE: To assess the rate of early (first trimester) and late (second and third trimester) fetal loss in women who are factor V Leiden homozygous.
Biron-Andréani, Christine, Gruel, Yves, Delahousse, Bénédicte, Lequerrec, Agnès, Dutrillaux, Fabienne, Polack, Benoit, Saladin-Thiron, Catherine, Boinot, Catherine, Bauters, Anne, Morange, Pierre-Emmanuel, Le Cam-Duchez, Véronique   +10 more
core   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Sustained pharmacodynamic effects of S‐ketamine on cortical excitability and resting‐state brain activity: A randomized, placebo‐controlled trial

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to investigate a set of pharmacodynamic biomarkers reflecting acute, delayed and sustained central nervous system effects of S‐ketamine, used as a tool compound for rapid‐acting antidepressant activity, with the goal of informing biomarker strategies for delayed antidepressant effects.
Catherine M. K. E. de Cuba, Annika A. de Goede, Joost. C. van Mechelen, Laura G. J. M. Borghans, Liam van der Aa, Erik Olofsen, Maria J. Juachon, Robert J. Doll, Amy Gillespie, Catherine J. Harmer, Gabriël E. Jacobs, Jules A. A. C. Heuberger   +11 more
wiley   +1 more source